These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36986795)

  • 1. Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder.
    Gauani H; Baker T; Li Z; Malinin VS; Perkins WR; Sullivan EJ; Cipolla D
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
    Ismat FA; Usansky HH; Villa R; Zou J; Teper A
    Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the biology of a long-acting inhaled treprostinil prodrug.
    Chapman RW; Corboz MR; Malinin VS; Plaunt AJ; Konicek DM; Li Z; Perkins WR
    Pulm Pharmacol Ther; 2020 Dec; 65():102002. PubMed ID: 33596473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension.
    Plaunt AJ; Islam S; Macaluso T; Gauani H; Baker T; Chun D; Viramontes V; Chang C; Corboz MR; Chapman RW; Li Z; Cipolla DC; Perkins WR; Malinin VS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension.
    Faria-Urbina M; Ung KT; Lawler L; Zisman LS; Waxman AB
    Pulm Circ; 2021; 11(2):20458940211012591. PubMed ID: 34035895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats.
    Chapman RW; Li Z; Chun D; Gauani H; Malinin V; Plaunt AJ; Cipolla D; Perkins WR; Corboz MR
    Pulm Pharmacol Ther; 2021 Feb; 66():101983. PubMed ID: 33346142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.
    Tiddens HA; Geller DE; Challoner P; Speirs RJ; Kesser KC; Overbeek SE; Humble D; Shrewsbury SB; Standaert TA
    J Aerosol Med; 2006; 19(4):456-65. PubMed ID: 17196074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hamilton M; Anderson M; Dhand R; Patmore O; Prime D; Taylor E
    J Aerosol Med Pulm Drug Deliv; 2023 Feb; 36(1):34-43. PubMed ID: 36695722
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.
    DeLong M; Wright J; Dawson M; Meyer T; Sommerer K; Dunbar C
    J Aerosol Med; 2005; 18(4):452-9. PubMed ID: 16379620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler.
    Abadelah M; Chrystyn H; Larhrib H
    Eur J Pharm Sci; 2019 Jun; 134():138-144. PubMed ID: 31005623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.
    Elkins MR; Robinson P; Anderson SD; Perry CP; Daviskas E; Charlton B
    Open Respir Med J; 2014; 8():1-7. PubMed ID: 24570763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.
    Farkas Á; Tomisa G; Kugler S; Nagy A; Vaskó A; Kis E; Szénási G; Gálffy G; Horváth A
    Int J Pharm X; 2023 Dec; 5():100167. PubMed ID: 36824288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOS™ dry powder inhaler device.
    Sahay S; Holy R; Lyons S; Parsley E; Maurer M; Weers J
    Pulm Circ; 2021; 11(1):2045894020985345. PubMed ID: 33532060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.
    Elkins MR; Anderson SD; Perry CP; Daviskas E; Charlton B
    Open Respir Med J; 2014; 8():8-13. PubMed ID: 24570764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil.
    Nguyen T; Chang C; Cipolla D; Malinin V; Perkins W; Viramontes V; Zhou J; Corboz M
    Expert Opin Drug Deliv; 2024 Aug; 21(8):1297-1305. PubMed ID: 39234785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
    Spikes LA; Bajwa AA; Burger CD; Desai SV; Eggert MS; El-Kersh KA; Fisher MR; Johri S; Joly JM; Mehta J; Palevsky HI; Ramani GV; Restrepo-Jaramillo R; Sahay S; Shah TG; Deng C; Miceli M; Smith P; Shapiro SM
    Pulm Circ; 2022 Apr; 12(2):e12063. PubMed ID: 35514770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date.
    Cassady SJ; Almario JAN; Ramani GV
    Drug Healthc Patient Saf; 2024; 16():51-59. PubMed ID: 38855777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.